The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Subclonal mutational heterogeneity and survival in cisplatin-resistant muscle-invasive bladder cancer.
 
David Liu
No Relationships to Disclose
 
Philip Abbosh
Honoraria - Ashion Advanced Individual Medicine
 
Daniel Keliher
No Relationships to Disclose
 
Brendan Reardon
No Relationships to Disclose
 
Kent William Mouw
No Relationships to Disclose
 
Amaro Taylor-Weiner
No Relationships to Disclose
 
Stephanie Anne Mullane
No Relationships to Disclose
 
Garam Han
No Relationships to Disclose
 
MinYuen Teo
No Relationships to Disclose
 
Jaegil Kim
No Relationships to Disclose
 
Hikmat Al-Ahmadie
No Relationships to Disclose
 
Gopa Iyer
No Relationships to Disclose
 
Essel Dulaimi
No Relationships to Disclose
 
David Chen
No Relationships to Disclose
 
Jean H. Hoffman-Censits
Honoraria - Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - Roche/Genentech
Research Funding - Sanofi
Travel, Accommodations, Expenses - Roche/Genentech
 
Scott L. Carter
No Relationships to Disclose
 
Joaquim Bellmunt
Consulting or Advisory Role - Astellas Pharma; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Elizabeth R. Plimack
Consulting or Advisory Role - Acceleron Pharma; Acceleron Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Lilly; Novartis; Synergene
Research Funding - Acceleron Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - AstraZeneca; Bristol-Myers Squibb; UpToDate
Consulting or Advisory Role - Agensys; AstraZeneca/MedImmune; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Lilly; Merck; Oncogenex; Roche/Genentech; Sanofi; Seagen
Research Funding - Agensys (Inst); Genentech (Inst); Genentech/Roche (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Viralytics (Inst)
Patents, Royalties, Other Intellectual Property - ERCC2 predicting cisplatin sensitivity
Travel, Accommodations, Expenses - Genentech/Roche
 
Eliezer Mendel Van Allen
Stock and Other Ownership Interests - Syapse
Consulting or Advisory Role - Genome Medical; Novartis; Roche; Syapse; Takeda; Third Rock Ventures
Research Funding - Bristol-Myers Squibb; Novartis